ADAP Advocacy and the Partnership for Safe Medicines (PSM) have issued a joint statement warning pharmacists that discounted HIV products purchased from online pharmacy-to-pharmacy (P2P) marketplaces fit the definition of suspect product under U.S. Food and Drug Administration (FDA) guidelines and the Drug Supply Chain Security Act. The organizations urge pharmacies not to buy from these platforms and to consider any HIV medicines obtained this way as suspect, requiring quarantine and verification before dispensing. Patients living with HIV/AIDS are potentially being put at risk.
PSM's Executive Director, Shabbir Imber Safdar, explained that a deeply discounted HIV product bought off the internet from an unknown seller who won't provide a pedigree qualifies as suspect even before the purchasing pharmacy receives it. The listing alone meets many of the FDA's risk criteria for illegitimacy, including deep discounts, an established pattern of fraud in the HIV drug supply chain over the last six years, unknown sellers, and incomplete transaction histories. Once received, the often-observed damage to the packaging confirms that the product must be quarantined and investigated.
Online P2P marketplaces are designed to help pharmacies manage inventory but pose risks of suspicious sales. Dispensers are required to quarantine and investigate suspect products and report illegitimate products to the FDA and partners within 24 hours. The warning issued to pharmacists by ADAP Advocacy and PSM is available online at https://www.safemedicines.org/diverted-hiv-meds-on-p2p-platforms.
Brandon M. Macsata, CEO of ADAP Advocacy, added that independent pharmacies have also been known to trade stock in less formal settings such as WhatsApp or Telegram. Those transactions are, if anything, more vulnerable and never advisable. He strongly urged pharmacists to heed the warning and avoid exposing patients to unnecessary risks.
The implications of this warning are significant for the healthcare industry and patients. Pharmacies that purchase HIV medications from unauthorized online platforms may inadvertently distribute counterfeit or adulterated drugs, compromising patient safety and treatment efficacy. For patients living with HIV/AIDS, receiving substandard or fake medications could lead to drug resistance, treatment failure, and increased health risks. The warning underscores the importance of adhering to FDA guidelines and the Drug Supply Chain Security Act to ensure the integrity of the pharmaceutical supply chain.
Healthcare providers and pharmacists must remain vigilant against diverted medications, which have become a growing concern in recent years. The joint statement serves as a critical reminder that discounted drugs from unknown sources should always be treated with suspicion. By following proper quarantine and verification procedures, pharmacies can help protect patients and maintain trust in the medication supply chain.
